Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12% stake in APT Medical Inc., a Shenzhen-based specialist in cardiac electrophysiology that went public on Shanghai’s STAR market in 2021. The acquisition will cost Mindray approximately RMB 6.652 billion (USD 926.6 million). Additionally, Mindray will purchase an extra 3.49% stake in APT from another domestic firm, bringing its total ownership to 24.61% upon completion of the transaction.
This strategic move is aimed at strengthening Mindray’s foothold in the cardiovascular medical devices sector.- Flcube.com
